AUROPHARMA.NS · Intrinsic value
Is Aurobindo Pharma Limited (AUROPHARMA.NS) overvalued or undervalued?
Aurobindo Pharma Limited (AUROPHARMA.NS) trades at the delayed market price of ₹1,653.10 a share. That price already implies revenue growth of 13.5% a year for 5 years. TickerWorth's fair value is ₹1,673.16 a share (priced within our range of ₹945.93 – ₹2,299.58). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is AUROPHARMA.NS fairly valued?
- Fair value
- ₹1,673.16
- Market price
- ₹1,653.10
- Upside to fair value
- +1.2%
- Verdict
- Priced within our range of ₹945.93 – ₹2,299.58
Reverse DCF: Today's price implies revenue growth of 13.5% a year for 5 years; our model assumes 10.1% a year on average over the same horizon.
What is AUROPHARMA.NS's TickerWorth Score?
Cheap against our estimate — but a weaker business
Compared with Healthcare companies in India
Its strongest point: looks cheap on the numbers. Its weakest: profitability is weak.
- Value · 94 of 100
Cheaper than 94% of Healthcare companies in India
- Price vs worth · 51 of 100
- Quality · 26 of 100
More profitable than 26% of Healthcare companies in India
- Financial health · 67 of 100
Financially stronger than 67% of Healthcare companies in India
- Growth · 46 of 100
Growing faster than 46% of Healthcare companies in India
- Momentum · 75 of 100
Outperformed 75% of Healthcare companies in India over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
AUROPHARMA.NS DCF valuation, input by input
At a recent price of ₹1,653, Aurobindo Pharma Limited (AUROPHARMA.NS) trades roughly at TickerWorth's blended fair value of ₹1,673 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices AUROPHARMA.NS in line with our estimate of what the business is intrinsically worth. Our fair value sits above the market, an implied +1.2% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values AUROPHARMA.NS at about ₹1,509 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Aurobindo Pharma Limited's projected free cash flows at a weighted-average cost of capital (WACC) of 9.6%, with a long-run terminal growth rate of 2.5%. About 73% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 13.5% annual revenue growth for AUROPHARMA.NS. Our base case instead compounds to about 10.1% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, AUROPHARMA.NS's modeled DCF value ranges from about ₹1,155 to ₹2,242 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Aurobindo Pharma Limited would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of AUROPHARMA.NS's intrinsic value. Figures update as new filings and prices come in.
Every input behind AUROPHARMA.NS's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | ₹349,352,890,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 15.2% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 16% → 13% → 10% → 7% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.00 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 575M |
| Market priceLast known price · as of 2026-10-19 13:20 UTC | ₹1,653 |
Change AUROPHARMA.NS's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Aurobindo Pharma Limited do?
What does it do?
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in India. The company employs roughly 29,209 people.
How does it make money?
The business turns 349.4B in annual revenue into profit. Out of every $100 of sales, about $15 is left as operating profit (operating margin of 15.2%), after a 59% gross margin on the products/services it sells. After all costs, taxes and interest, 10.6% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.2× equity), and is currently profitable.
AUROPHARMA.NS insider trading
Insider filings are available for US-listed companies only.
Common questions
What is AUROPHARMA.NS's intrinsic value?
TickerWorth's blended fair value for Aurobindo Pharma Limited (AUROPHARMA.NS) is ₹1,673 per share, versus a market price of ₹1,653 (roughly at fair value).
Is AUROPHARMA.NS overvalued or undervalued?
On our blended fair value AUROPHARMA.NS looks in line with fair value at ₹1,653. This is an educational estimate, not advice.
What discount rate is used for AUROPHARMA.NS?
A WACC of 9.6% and a terminal growth rate of 2.5%.
Is Aurobindo Pharma stock undervalued?
TickerWorth's fair value for Aurobindo Pharma Limited (AUROPHARMA.NS) is ₹1,673.16 against a market price of ₹1,653.10. Our read: Priced within our range of ₹945.93 – ₹2,299.58. This is a model estimate, not investment advice.
Aurobindo Pharma (AUROPHARMA.NS) DCF valuation and fair value
Our fair value for Aurobindo Pharma Limited (AUROPHARMA.NS) is ₹1,673.16, built on a 9.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Aurobindo Pharma stock?
Today's price implies revenue growth of 13.5% a year for 5 years; our model assumes 10.1% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of ₹1,653.10. A model estimate, not investment advice.
Aurobindo Pharma (AUROPHARMA.NS) insider trading
We have no recent SEC Form 4 insider filings on file for Aurobindo Pharma Limited (AUROPHARMA.NS). Form 4 covers US-listed companies only.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.